ALPG and ovarian cancer: They pursued two such multiantigen targeting strategies for GBM, EGFRvIII-SynNotch CAR and EphA2 or IL13Ra2 CARs (23), and approaches for mesothelioma and ovarian cancer involving alkaline phosphatase placental-like 2 (ALPPL2)-synNotch CAR and MCAM, MSLN or HER2 CAR (24).